3‐(2,4‐Dimethoxybenzylidene)‐anabaseine: A promising candidate drug for Alzheimer's disease?

Zawieja, Philippe; Kornprobst, Jean‐Michel; Métais, P

doi:10.1111/j.1447-0594.2011.00827.x

Cited by 21 publications

(8 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They are composed of different combinations of five subunits (α, β, γ, δ and ε) that form cysteine-loop ligand-gated cation channels permeable to Na + and K + and, to variable amounts of Ca 2+ . In the brain, the most abundant subunits are homomeric α7 subtype and the heteromeric α4β2 subtype, which are highly expressed in brain regions that develop AD neuropathology [ 68 , 69 , 70 ]. The binding of an agonist to a α7 nAChR leads to conformational changes and, consequently, the opening of the channel allowing the passage of ions.…”

Section: Marine Natural Productsmentioning

confidence: 99%

See 1 more Smart Citation

Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer’s Disease

et al. 2020

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a multifactorial disease characterized by the presence of amyloid plaques, neurofibrillary tangles, and nerve cell death that affects, mainly, older people. After decades of investigation, the search for an efficacious treatment for AD remains and several strategies can be and are being employed in this journey. In this review, four of the most promising strategies, alongside with its most promising agents under investigation or development are highlighted. Marine natural products (MNP) are a source of unique chemical structures with useful biological activities for AD treatment. One of the most promising compounds, a marine-derived acidic oligosaccharide (GV-971) just passed phase III clinical trials with a unique mechanism of action. Combination therapy and multitargeted-directed ligand therapy (MTDL) are also two important strategies, with several examples in clinical trials, based on the belief that the best approach for AD is a therapy capable of modulating multiple target pathways. Drug repurposing, a strategy that requires a smaller investment and is less time consuming, is emerging as a strong contender with a variety of pharmacological agents resurfacing in an attempt to identify a therapeutic candidate capable of modifying the course of this disease.

show abstract

Section: Marine Natural Productsmentioning

confidence: 99%

“…Following activation, the channel rearranges resulting in a loss of biological response [ 71 ]. The nAChR is a target for AD, because Aβ binds to these receptors, especially to the α7 subtype, and can alter the normal functionalization of the receptor leading to the initialization of Aβ [ 68 ].…”

Section: Marine Natural Productsmentioning

confidence: 99%

Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer’s Disease

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It was also shown to improve memory-related behaviour in Sprague–Dawley rats [50]. DMXBA in Alzheimer’s has been reviewed by Zawieja et al [51], and Kem et al reviewed studies on the use of anabaseine and DMXBA against memory loss and schizophrenia [46]. A comprehensive paper by Rangel and Falkenberg discussed the recent status of clinical trials with regard to compounds of marine origin and their derivatives in the pharmaceutical pipeline [52].…”

Section: Ribbon Worm Toxinsmentioning

confidence: 99%

The Toxins of Nemertean Worms

Göransson

Jacobsson

Strand

et al. 2019

Toxins

View full text Add to dashboard Cite

Most ribbon worms (phylum: Nemertea) are found in marine environments, where they act as predators and scavengers. They are characterized by an eversible proboscis that isused to hunt for prey and thick mucus covering their skin. Both proboscis and epidermal mucus mediate toxicity to predators and preys. Research into the chemical nature of the substances that render toxicity has not been extensive, but it has nevertheless led to the identification of several compounds of potential medicinal use or for application in biotechnology. This review provides a complete account of the current status of research into nemertean toxins.

show abstract

“…76 Additionally, GTS-21 is a selective agonist of the a7 nicotinic receptor, showed promising characteristics during Phase II clinical trial. 77 Fig. 2 and Table S2 † show cholinergic inhibitors in clinical trials.…”

Section: Cholinergic Drugsmentioning

confidence: 99%